Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
D-cycloserine augmentation of exposure and response prevention for obsessive-compulsive disorder
NL-OMON30642Phase 2Not yet recruiting
- Sponsor
- Meerkanten
- Start
- Sep 2007
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in obsessive compulsive disorder (OCD) comparing D-cycloserine + ERP with Placebo + ERP (2 arms). Primary endpoint: Change in Yale-Brown Obsessive Compulsive Scale. Planned start Sep 2007; status: not yet recruiting.
02
Drugs
d-cycloserine
03
Conditions
obsessive compulsive disorder (OCD)
Beyond the preview
Go deeper on NL-OMON30642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON30642.